NICE TAs

13/05/2020

TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer

13/05/2020

TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer

13/05/2020

TA434: Elotuzumab for previously treated multiple myeloma (terminated appraisal)

13/05/2020

TA408: Pegaspargase for treating acute lymphoblastic leukaemia

13/05/2020

TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction

13/05/2020

TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors

13/05/2020

TA506: Lesinurad for treating chronic hyperuricaemia in people with gout

05/05/2020

TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

05/05/2020

TA417 : Nivolumab for previously treated advanced renal cell carcinoma

05/05/2020

TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer

04/05/2020

TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma

04/05/2020

TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer

04/05/2020

TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

04/05/2020

TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab

04/05/2020

TA442: Ixekizumab for treating moderate to severe plaque psoriasis

04/05/2020

TA479: Reslizumab for treating severe eosinophilic asthma

04/05/2020

TA413: Elbasvir–grazoprevir for treating chronic hepatitis C

04/05/2020

TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine

04/05/2020

TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea

04/05/2020

TA463: Cabozantinib for previously treated advanced renal cell carcinoma